The DOI matches its Crossref record; 212 of the 213 references it cites were found in a registry or an index.
New Approaches in the Treatment of Hypertension
Abstract
Hypertension is the most common modifiable risk factor for cardiovascular disease and death, and lowering blood pressure with antihypertensive drugs reduces target organ damage and prevents cardiovascular disease outcomes. Despite a plethora of available treatment options, a substantial portion of the hypertensive population has uncontrolled blood pressure. The unmet need of controlling blood pressure in this population may be addressed, in part, by developing new drugs and devices/procedures to treat hypertension and its comorbidities. In this Compendium Review, we discuss new drugs and interventional treatments that are undergoing preclinical or clinical testing for hypertension treatment. New drug classes, eg, inhibitors of vasopeptidases, aldosterone synthase and soluble epoxide hydrolase, agonists of natriuretic peptide A and vasoactive intestinal peptide receptor 2, and a novel mineralocorticoid receptor antagonist are in phase II/III of development, while inhibitors of aminopeptidase A, dopamine β-hydroxylase, and the intestinal Na(+)/H(+) exchanger 3, agonists of components of the angiotensin-converting enzyme 2/angiotensin(1-7)/Mas receptor axis and vaccines directed toward angiotensin II and its type 1 receptor are in phase I or preclinical development. The two main interventional approaches, transcatheter renal denervation and baroreflex activation therapy, are used in clinical practice for severe treatment resistant hypertension in some countries. Renal denervation is also being evaluated for treatment of various comorbidities, eg, chronic heart failure, cardiac arrhythmias and chronic renal failure. Novel interventional approaches in early development include carotid body ablation and arteriovenous fistula placement. Importantly, none of these novel drug or device treatments has been shown to prevent cardiovascular disease outcomes or death in hypertensive patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, despite blood pressure’s association with many unique dis- eases, by itself it does not provide information regarding the mechanisms of any given disorder.”
From Methods and challenges for assessing heterogeneity (2020) · cites this paper as [42]
Citations
Cites
2013 ESH/ESC Guidelines for the management of arterial hypertension
Authors Task Force Members, Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., Christiaens, T., Cífková, R., Backer, G. D., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,739
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Endarterectomy for Asymptomatic Carotid Artery Stenosis
WALKER, M. D. (1995) · JAMA · doi:10.1001/jama.1995.03520420037035 · Cited by 4,435
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F. M., Remme, W. J., Cody, R. J., Castaigne, A., Pérez, A. J. P., Palensky, J., & Wittes, J. T. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Resistant Hypertension: Diagnosis, Evaluation, and Treatment
Calhoun, D. A., Jones, D. W., Textor, S. C., Goff, D. C., Murphy, T. P., Toto, R. D., White, A. J., Cushman, W. C., White, W. B., Sica, D. A., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.189141 · Cited by 2,240
A Controlled Trial of Renal Denervation for Resistant Hypertension
Bhatt, D. L., Kandzari, D. E., O'Neill, W. W., D'Agostino, R., Flack, J. M., Katzen, B. T., Leon, M. B., Liu, M., Mauri, L., Negoita, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402670 · Cited by 2,186
Self-citation
Research works printed but not linked: 7
- Van der Meer I Benigni A Parvanova A Iliev I Sharma S Cruz J et al.. Pressure control by combined ECE/NEP inhibitor on top of losartan: a randomized cross-over placebo-controlled clinical trial in patients with type 2 diabetes and albuminuria. Twelfth International Conference on Endothelin; 2011. p. 50.
- Wong K, Zhang L-N, Vincelette J, Chen D, Tran V, Mehra U, Gless R, Anandan S-K, Webb HK, MacIntyre U, Wang Y-X. A novel inhibitor of soluble epoxide hydrolase, AR9281, improves glucose homeostasis in diet-induced obese mice. American Diabetes Society 69th Scientific Sessions. New Orleans. Diabetes. 2009;58:A436 (1698-A).
- 10.1056/NEJMc1402687 · DOI
- Walton T, Hardin S, Rothman M, Whitbourn R. Renal artery denervation with a new simultaneous multielectrode catheter for treatment of resistant hypertension: Six month results from the symplicity spyral first-in-man study. EuroPCR. 2014;Euro14A–OP209.
- Verheye S, Ormiston J, Kuck KH, Bergmann M, Sievert H, Torsello G, Dens JAY, Grube E, Colombo A, Vogel B, Voskuil M, Daemen J. Safety and effectiveness of catheter-based renal sympathetic denervation for the treatment of resistant hypertension: 12-month results of the rapid study. EuroPCR. 2014:14A–OP208.
- Zeller T, Andersson B, Bohm M, Kuck KH, Sievert H, Graf T, Kahlert P, Daemen J. The paradise renal denervation system: Initial clinical results from the achieve study. EuroPCR. 2014:14A–OP205.
- Shetty S, Blessing E, Roenschein U, Scheinert D, Diehm N, Jonas M. Renal denervation using the novel therapeutic intra-vascular ultrasound (tivus) catheter system - preliminary report of first-in-man safety and performance study. EuroPCR. 2014:14A–OP206.
Cited by
Sorted by citations
Oparil, S., Acelajado, M. C., Bakris, G. L., Berlowitz, D. R., Cífková, R., Dominiczak, A. F., Grassi, G., Jordan, J., Poulter, N. R., Rodgers, A., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.14 · Cited by 1,167
Self-citationAdherence in Hypertension: A Review of Prevalence, Risk Factors, Impact, and Management
Burnier, M., & Egan, B. M. (2019) · Circulation Research · doi:10.1161/circresaha.118.313220 · Cited by 878
Kreutz, R. H., Algharably, E. A. E., Azizi, M., Dobrowolski, P., Guzik, T. J., Januszewicz, A., Persu, A., Prejbisz, A., Riemer, T., Wang, J., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa097 · Cited by 366
Coulson, L. B., Danser, A. H. J., Poglitsch, M., Touyz, R. M., Burnett, J. C. J., Llorens‐Cortés, C., Ehlers, M. R., & Sturrock, E. D. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017129 · Cited by 346
Huang, S., Wang, J., Liu, F., Liu, J., Cao, G., Yang, C., Liu, W. Y., Tu, C., Zhu, M., & Xiong, B. (2020) · Hypertension Research · doi:10.1038/s41440-020-0485-2 · Cited by 227
Metadata
- Authors
- Oparil, S., & Schmieder, R. E.
- Affiliations
- University of Alabama at Birmingham Hospital (US)
- Venue
- Circulation Research
- Published
- 2015-03-13
- Volume
- 116
- Issue
- 6
- Pages
- 1074-1095
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2138173257
- Cited by
- 276
- References
- 213
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 20 · 2023: 26 · 2022: 23 · 2021: 27 · 2020: 30 · 2019: 33 · 2018: 26 · 2017: 29 · 2016: 24 · 2015: 14
- FWCI
- 22.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Circulation Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- hypertension, antihypertensive drugs, treatment-resistant hypertension, vasopeptidase inhibitors, aldosterone synthase inhibitors, soluble epoxide hydrolase inhibitors, mineralocorticoid receptor antagonists, dopamine beta-hydroxylase inhibitor, Na+/H+ exchanger 3, baroreflex activation therapy, arteriovenous fistula, cardiovascular disease prevention, uncontrolled hypertension
- MeSH terms
- Mineralocorticoid Receptor Antagonists, Animals, Antihypertensive Agents, Arteriovenous Shunt, Surgical, Carotid Body, Clinical Trials as Topic, Electric Stimulation Therapy, Enzyme Inhibitors, Female, Humans, Hypertension, Ion Channels, Kidney, Kidney Tubules, Pre-Eclampsia, Pregnancy, Pressoreceptors, Receptors, Cell Surface, Renal Artery, Renin-Angiotensin System, Sympathectomy, Sympathetic Nervous System, Drug Design, Multicenter Studies as Topic, Drugs, Investigational, Stents, Comorbidity, Randomized Controlled Trials as Topic, Baroreflex, Oxidative Stress, Decompression, Surgical, Models, Animal, Therapies, Investigational, High-Intensity Focused Ultrasound Ablation, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
